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Metabolite-Based Internal Doses Used in a
Risk Assessment of Benzene
by A. John Bailer*t and David G. Hoel*
Riskassessments ofbenzene have been based upon both human and animal studies. In thispaper, metabolite
information is used to construct an internal dose (a surrogate ofthe biologically effective dose) for a given
administered dose. The relationship between the administered dose and this internal dose is nonlinear and
is well described by a Michaelis-Menten function. The administered doses from the National Toxicology Pro-
gram's rodent carcinogenicity study ofbenzene are transformed into internal doses, and these internal doses
are used in conjunction with a multistage model to compare previous estimated virtually safe doses (VSD)
associated with small added health risks. The ratio ofVSD forthe administered dose risk assessmentto the
VSD from the internal dose risk assessment was approximately 1.0 forthe F344/N rats and ranged from 2.5
to 5.0 forB6C3F, mice in the National Toxicology Program study. For an occupational exposure of1 ppm,
a risk estimate of0.7 excess cancers/1000 exposed with an upper bound of3.5/1000 was obtained for a total
metabolite internal dose risk assessment. Riskestimates based upon internal dosesconstructed from levels
ofthe toxic metabolites ofbenzene a're also presented. The implication ofa dose-rate study ofbenzene me-
tabolism for risk assessment is discussed, and finally, suggestions for better characterization ofthe dose-
response function for benzene are provided.
Introduction
Benzene is an important chemical in the manufacturing
of a variety ofproducts including petroleum and rubber
products. Because ofits prevalent use and occupational
exposures, benzene has been extensively studied for ad-
verse human health effects. Benzene is awell-established
leukemogen and causes other health effects, including
decreased bone marrow cellularity and increased chro-
mosomal aberrations in lymphocytes and marrow. The
health effects ofbenzene are summarized in a variety of
publications (1,2).
As with any identified health hazard, the regulation of
benzene exposure becomes animportant issue. An impor-
tant component ofregulatory decisions is the projection
of health risks at current occupational exposure levels.
Two general classes ofstudies are frequently used in de-
veloping these risk projections for benzene.
Studies in the first class are epidemiological investiga-
tions in which observations are made on human popula-
tions exposed to benzene. The populations frequently
studied are workers who are potentially exposed to high
levels of benzene. Such studies include benzene ex-
posures in rubber hydrochloride workers (3,4), chemical
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plant workers (5), and shoe workers(6). Avariety ofrisk
estimation models havebeenapplied to these data(7-11),
and risks in the range of20 to 80 excess leukemia deaths
per 1000 workers exposed to 10 ppm for 30 years have
been predicted.
The second class of studies are animal experiments
often involving the chronic administration of benzene.
These studies assess toxicity with respect to dose re-
sponse, dose rate, and presumed mechanism of action.
Dose-response studies arefrequentlyused to do riskpro-
jection. Dose-rate studies, on the other hand, examine a
question of considerable relevance in epidemiological
studies: Is short-term, high-level exposure more toxic
than a chronic low-level exposure?
In dose-response studies, high doses ofbenzene are ad-
ministered by gavage or inhalation to laboratory animals
with the typical end point ofneoplasia being examined.
The most common cancers observed in the benzene
studies are Zymbalgland carcinomas, squamous cell car-
cinomas, lymphomas, and alveolar/bronchiolar carci-
nomas (12,13). Risk projections based upon these data
have beenreported(9). These calculations attempt to pre-
dictthe doses associated with very smalllevels ofadded
cancer risk (e.g., 1 in 106). The dose associated with the
small addedriskis the so-called virtually safe dose(VSD).
Use of these studies to predict human health risks are
criticized for avariety ofreasons, includingthe extrapo-
lation of animal response to human response (e.g., hu-
mans do not have Zymbalglands so whatriskdoes a com-
pound causingrodent Zymbalgland carcinomas pose forBAILER AND HOEL
humans?) and the extrapolation of effects at high ex-
posures to those in low-dose regions.
The extrapolation from high doses to low doses is part
of a larger problem. The external exposure to a com-
pound is not necessarily linearly related to dose of the
compound at the target sites. Ifa chemical (or its metabo-
lites) interact with DNA, then it may be more meaning-
ful to relate tumorigenic response to DNA adducts
(14,15). Alternatively, the toxic effect may notbe directly
related to levels ofthe parent compound but may be as-
sociated with levels ofparticular metabolite(s) ofthe par-
ent compound (16). The nonlinearity of the response to
the administered dose (AD) may simply represent the
nonlinearity relating the AD to the relevant internal dose
(ID) causedpossibly by the saturation ofpathways in the
metabolism of the administered compound.
Recently, studies ofthe production ofbenzene metabo-
lites as a function ofadministered doses ofbenzene have
been reported (17,18). In this paper, the benzene metabo-
lite study (17) is used to derive an internal dose, which
is then modeled as a function ofthe administered dose.
This relationship is applied to the NTP dose-response car-
cinogenicity study ofbenzene, and previously calculated
VSDs are examined. In addition to reporting this risk
projection, the implications of a dose-rate study ofben-
zene (18) and metabolite levels are discussed.
Constructing and Modeling an
Internal Dose
In the Sabourin et al. study(12), F344/N rats, Sprague-
Dawley (S-D) rats and B6C3F1 mice were exposed toben-
zene by one ofthree routes (gavage, inhalation and IP).
We shall be concerned with the gavage exposures as the
NTP gavage study will be our source ofcarcinogenicity
data. The gavage dose administered to the rodents
(Tablel) covered a range of 0.5 to 300 mg/kg for the
F344/N rats, 0.5 to 150 mg/kg for the B6C3F1 mice, and
0.5 and 150 mg/kg for the S-D rats. The elimination of
benzene was measured collecting all exhalantusing a CO2
trap (KOH) and an ethanol trap (EOH), urine, feces, car-
cass, and pelt. KOH, urine, feces, and pelt are all indica-
tors ofbenzene metabolism, and EOH is an indicator of
unmetabolized benzene. Basic results from this study in-
clude: a) at doses > 15 mg/kg, an increasing percentage
ofbenzene was exhaled unmetabolized in both rats and
mice, which implies saturation ofuptake or metabolism;
and b) at doses 2 50mg/kg, total metabolite production
in the mice plateaus with respect to the administered
Table 1. Details of gavage doses administered in the Sabourin
et al. study of benzene (17).
Gavage dose, mg/kg
Species 0.5 5 15 50 150 300
B6C3F, x x x x x
F344 x x x x x x
S-D x x
dose. These results indicate that anonlinear function will
be important for relating administered dose to an inter-
nal dose. An internal dose might be the total amount of
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Thus, the ID is constructed as thefraction ofthe ADthat
corresponds to metabolized benzene.
The plots ofID versus AD forthe B6C3F1 mice andthe
F344 rats are presented in Figures 1 and2, respectively.
From these plots, the relationship between the ID and
the AD appears nonlinear (although the rat data may be
adequately described by a line). A reasonable model for
such arelationship wouldbe aMichaelis-Mentenfunction,
i.e.,
aA D I D =
3+A D (2)
Such afunction was to fit to these data, and estimates of
the parameters a and p are given in Table 2. The fitted
Michaelis-Menten function is superimposed over the data
points in Figures 1 and 2.
Risk Calculations Using AD and ID
Risk projections will be made using the NTP gavage
study ofbenzene (13). This study indicated atumorigenic
response for a variety of sites over a range of doses for
which metabolite information is now available. The doses
used in the NTP study and the ID corresponding to these
ADs are given in Table 3. For the rat data, the relative
doses in the AD scale is maintained in the ID dose scale.
In otherwords, a doubling on the AD scale (e.g., from 50
mg/kg to 100mg/kg) is matched by an approximate dou-
bling on the ID scale (e.g., from 29.75 mg/kg to 55.75
mg/kg). Thisrelative dosingis notpreservedforthe mice
data.
The multistage model is frequently used to model
tumorigenic response data and has been used in aprevi-
ousrisk assessment ofbenzene (9). The basicform ofthis
model for a four dose group experiment is
P(di)= 1-ex p -(qo+qj di+q2di +q3di)} (3)
where P(dO) corresponds to the lifetime probability oftu-










FIGURE 1. Plot of internal dose versus administered dose for B6C3FI
mice with superimposed Michaelis-Menten fitted curve. Some ofthe
plotted points represent multiple observations.
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FIGURE 2. Plot of internal dose versus administered dose for F344/N
rats with superimposed Michaelis-Menten fitted curve. Some ofthe
plotted points represent multiple observations.
Table 2. Michaelis-Menten parameter estimates and SEs for fitting
the ID-AD relationship.
Table 3. NTP benzene gavage administered doses (AD) and
corresponding internal doses (ID) based upon a Michaelis-Menten
function.
Species Sex AD, mg/kg ID, mg/kg
















q2, and q3 are nonnegative parameters that are esti-
mated. Maximum likelihood parameter estimates for qo,
qi, q2, and q3 were calculated, and the lower bound on a
dose associated with an added risk of 1 in 106 was ob-
tained (19). We are not advocating the calculation of
VSDs for risk levels of one in a million. The dose associ-
ated with such a small risk is clearly below the lowest
tested dose group, and is very dependent on the choice
of the dose-response function. Our interest is solely to
compare the effects of a change from an AD to an ID on
the estimation of VSDs for a model and risk level used
inpreviousrisk assessments ofbenzene (9). Once this safe
dose is determined for the risk assessment based upon
the ID scale, the conversion back to the AD dose scale
can be done directly by inverting the Michaelis-Menten
function, i.e.,
AD = Ox I D
a- ID (4)
where the estimates of a and P are used in this formula.
The safe doses calculated from the AD and ID risk as-
sessments are presented in Table 4. The ID safe doses
have been converted to the AD dose scale. The ratio of
AD-based safe dose to the ID-based safe dose is also pre-
sented in this table. This ratio is essentially 1.0 for the
rat data. This result is as expected since the AD relative
dose spacing waspreserved on the ID scale. The ratio for
mice ranged from 2.5 to 5.0 for the mice. Thus, the non-
linearity between the ID and AD was converted into a
VSD at least 2.5 times smaller than would have been
predicted based solely upon the AD risk assessment.
Historically, linear projections of risk into low-dose
regions have been performed (11). A natural question
about internal dose construction is: Does the tumorigenic
response exhibit a linear relationship with this dose mea-
sure? We examined the shape ofthe tumor-response dose
relationships in the NTP study forboth administered and






aNumbers in parentheses are SEs.
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Table 4. The 95% lower bound estimates for the dose associated with an added risk of 10- .a
Safe dose
AD ID Dose (AD)/dose (ID)
B6C3F1 male mice
All squamous cell carcinomas 0.129 x 10-3 0.256 x 10-4 5.3
Alveolar/bronchiolar carcinomas 0.238 x 10-3 0.780 x 10-4 3.1
Lymphoma, NOS 0.357 x 1i-0 0.139 x 10-3 2.6
B6C3F, female mice
All squamous cell carcinomas 0.667 x 10 0.281 x 10 2.4
Mammary gland carcinoma, NOS 0.270 x 10-3 0.120 x 10 2.3
Alveolar/bronchiolar carcinomas 0.366 x 10 0.141 x 10-3 2.6
Malignant lymphoma 0.271 x 10- 0.611 x 10-4 4.4
F344/N male rats
Zymbal gland carcinomas 0.383 x 10' 0.319 x 10' 1.2
All squamous cell carcinomas 0.339 x 10 0.282 x 10-3 1.2
F344/N female rats
Zymbal gland carcinomas 0.238 x 10-3 0.217 x 10-3 1.
All squamous cell carcinomas 0.479 x 10 0.435 x 10 1.
Squamous cell carcinoma of
the preputial gland 0.123 x 10-3 0.125 x 10-3 1.0
aEstimates from AD-based and ID-based risk assessments.
sented in Table 5. These shape assessments are simply
rough descriptions based upon examining the tumori-
genic response-benzene dose patterns.
It is worth noting the potential influence of shape on
riskprojection when usinginternal doses versususingad-
ministered doses. As an example, we consider all squa-
mous cell carcinomas in male B6C3F1 mice. This response
is particularly relevant because it has been used in other
benzene risk assessments when extrapolating animal to
human risk (9). In Figure 3, the observed incidence ofall
squamous cell carcinomas is plotted against the ad-
ministered dose for male mice. The curve representing
the bestfitting multistage model is overlayed on thisfig-
ure. This dose-respQnse relationship appears almost lin-
ear(slightly sublinear or even sigmoidal?). A similarfig-
ure for this tumor site using the internal dose scale is
presented in Figure 4. In this figure, the dose-response
curve is very nonlinear (hockey stick shape). (The shape
Table 5. Shapes of the tumorigenic response-AD/ID curves.a
AD scale ID scale
B6C3F, male mice
All squamous cell carcinomas L/- -
Alveolar/bronchiolar carcinomas + L
Lymphoma, NOS L L
B6C3F, female mice
All squamous cell carcinomas
Mammary gland carcinoma, NOS L
Alveolar/bronchiolar carcinomas + L
Malignant lymphoma + +
F344/N male rats
Zymbal gland carcinomas L L
All squamous cell carcinomas L L
F344/N female rats
Zymbal gland carcinomas L L
All squamous cell carcinomas L L
Squamous cell carcinoma of + +
the preputial gland
aAbbreviations: (L) linear; (+) superlinear; (-) sublinear.
ofthe dose-response relationship forall squamous cell car-
cinomas differs for the other three sex-species conditions.
This relationship is nonlinear on both the administered
dose and internal dose scalings for female mice and is
roughly linear forboth dose scalings in both sexes ofthe
rats.) Given the linear dose-response using the ad-
ministered dose and hockey stick dose-response relation-
ship using the internal dose, one might expect that the
r-isk assessment based upon the ID would lead to a larger
safe dose associated with agiven specified small risk. This
is in fact observed for the point estimates ofthe dose as-







FIGURE 3. Plot ofprobability ofall squamous cell carcinomas versus ad-
ministered dose for B6C3F, male mice with superimposed multistage
model fitted curve(solidline), andlinearregression through the origin
(dashed line). Quantal response data points along with 95% confidence






FIGURE 4. Plot ofprobability ofall squamous cell carcinomas versus in-
ternal dose for B6C3F, male mice with superimposed multistage
model fitted curve (solid line). Dashed lines connect the observed
quantal responses at each dose value. The quantal response data
points along with 95% confidence limits are presented as solid circles
with vertical lines.
AD; 4.3 x 10- 'for ID-based risk estimates transformed
back to the AD scale). When the linearized form of the
multistage model is used to derive the lowerbound on the
dose associated with 10 6risk(19), the ID-based estimate
is five times smaller than the AD-based estimate. A
forced linearized multistage model fit is inappropriate for
describing the internal dose-tumorigenic response rela-
tionship if the data are truly nonlinear and may lead to
misleadingresults. In fact, the routine use ofany compli-
cated computermodel for low dose extrapolation is worth
questioning.
Individual Benzene Metabolites
Overall metabolite production as an ID is confounded
somewhat since at higher doses ofbenzene the metabo-
lism may shift to the detoxification pathways. This may
represent a shift in the balance ofactivation/deactivation
pathways. Using the levels ofthe toxic metabolites helps
to avoid this problem and brings us one step closer to the
biologically effective dose. Apreliminary risk assessment
of benzene has been conducted using levels of toxic
metabolites to construct an internal dose. A dose-
response study of individual metabolites has been con-
ducted (18). In this study, B6C3F1 mice and F344/N rats
were exposed by gavage (at doses 1, 10, and 200 mg/kg)
and by inhalation (at doses 5, 50, and 600 ppm); animals
were sacrificed at fixed time points, and levels of in-
dividual benzene metabolites were determined for the
liver, lung, blood, and urine. For each dose, site, and
metabolite, a concentration-time profile was obtained. We
focus our attention on two indicators of the toxic path-
ways ofbenzene metabolism(18), namely the metabolites
muconic acid (MUC) and hydroquinone glucuronide
(HQG). Internal doses were constructed by summingthe
area under the metabolite concentration-time curves
(AUCs) forMUC and HQG over all tissue andfluid sam-
ples. As was previously done, a Michaelis-Menten func-
tion was used to model the ID-AD relationship (for HQG:
a = 1.84, p = 261.45; forMUC: a = 8.14, p = 365.21). Simi-
larcalculations were done forthe rats(for HQG: a = 0.03,
p = 25.63; for MUC: a = 0.29, p = 45.91). The internal
doses based upon HQG and MUC will be denoted
ID(HQG)and ID(MUC), respectively. Valuesforthese in-
ternal doses are presented for the NTP administered
doses in Table 6. From this table, the ID-AD relationship
appears roughly linear for the mice and very nonlinear
for the rats. The nonlinearity in the ID(HQG)-AD rela-
tionship for rats may be artificial because the observed
levels ofHQG are extremely small with little to no HQG
detected even athigh administered doses. There are only
nine data points fit by the Michaelis-Menten curve, and
these points exhibit tremendous variability especially at
the highest AD. The linearity inthe ID-ADfitted curves
for mice may also have similarproblems. In the spirit of
exploration and recognizing the possible problems in the
ID-AD fitted curves, we used these ID(HQG) and
ID(MUC) doses to see the effects this information has on
benzene risk estimation. The details ofthis risk estima-
tion aregiven inthe section on the "Extrapolation to Hu-
man Exposure."
Benzene Dose-Rate Studies
From the risk estimation discussed previously, we see
the potential importance ofthe ID-AD relationship in ob-
taining safe dose estimates. Short-term, high-level ex-
posure may lead to greater toxic response than chronic,
low-level exposure. The datato address such anissue has
been described (18), and we would like to summarize
some ofthe early analyses ofthese data and discuss the
Table 6. NTP benzene gavage administered doses and
corresponding internal doses based upon AUC for hydroquinone
glucuronide and muconic acid.a
Species Sex AD, mg/kg ID(HQG), mg/kg ID(MUC), mg/kg
















aAbbreviations: AD, administered dose; ID, internal dose; HQG,
hydroquinone glucuronide; MUC, muconic acid.
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potential implication ofsuch data on the risk estimation
process.
In these dose-rate experiments, B6C3F, mice and
F344/N rats were exposed by inhalation at one ofthree
dose rates: a) 600 ppm for 30 min; b) 150 ppm for2 hr; or
c) 50 ppm for 6 hr. Animals were sacrificed at fixed time
points, and levels ofindividual benzene metabolites were
determined for the liver, lung, blood, and urine. Foreach
dose rate, tissue or body fluid, and metabolite, a
concentration-time profile was obtained. The area under
the concentration-time curve again was used as a sum-
mary of the total metabolite burden.
As before, the two indicators ofthe toxic pathways of
benzene metabolism (muconic acid and hydroquinone
glucuronide) are considered. In general, the AUC for
MUC and HQG was significantly greater in the lower-
dose exposure groups (2 hr, 150 ppm and 6 hr, 50 ppm)
than in the short-term, high-exposure group (30 min., 600
ppm) in the liver, blood and lung ofthe mice. The AUC
for the lower exposure groups was roughly two to three
times the AUC for the short-term, high-exposure group.
In general, the opposite was true for the rats where the
short-term, high-exposure group had a greater toxic
metabolite burden than the lower exposure groups by a
factor ofabout 1.5 to 2. Thisresult is consistent with the
observed saturation ofmetabolic pathways in mice and
lack of saturation in rats (17).
The implication ofthis dose-rate study for human risk
estimation depends upon which animal model, the mouse
or the rat, provides the best analog for human metabo-
lism ofbenzene. Ifhumanmetabolism is clearly saturable
like the mouse, then exposure measures in epidemiolog-
ical studies should weigh longer, lower dose exposures
more heavily than short-term, high-dose exposure. The
opposite weighting scheme shouldbe used ifhuman me-
tabolism is more like the rat in that high-dose exposures
have not saturated the metabolic pathways.
Extrapolation to Human Exposure
The ultimate goal ofany risk assessment process is to
predict human risk. Epidemiological studies have many
difficulties, including the assessment ofexposure. This is
typically not an issue in animal studies; however, there
is considerable uncertainty in the extrapolation ofthese
studies to the human condition. Not only must the ques-
tion ofspecies extrapolation be addressed, but the issue
of generalizing one route of exposure (e.g., gavage) to
another route of exposure (e.g., inhalation) frequently
mustbe addressed. Both ofthese questions are discussed
in order to use the multistage model results.
The question ofextrapolating inhalation togavage dos-
ing is addressed by assuming that each part per million
ofinhaled benzene contains acertainmassofbenzene per
cubic meter [3.19 mg/m3 is frequently used (9)], that the
breathing rate ofhumans in an 8-hr period is known [10
m3 (9)], and that all of the inhaled benzene is absorbed.
The conversion from rodents to humans is based upon
what isbelieved to be the dose unitsforequivalent risks.
Following the methods of Crump and Allen (9), milli-
gram/kilogram/day is consideredthe equivalent doseunit,
and the milligram/kilogram/day dose d' for humans ex-
posed to benzene at a level ofE ppm per work day for a
lifetime is
(3.19mg/ m 10 m 1
1 ppm 8 - hr day, 70 kg (5)
where 70kgis assumedtobe the average weight ofahu-
man. Forexample, a 1 ppm exposure (i.e., E = 1)leads to
an equivalent milligram/kilogram/day dose of 0.456. If
this dose is input into the multistage model formale mice
all squamous cell carcinomas, thenapointestimate of0.69
excess cancers/1000 exposed (with an upper bound of
3.52/1000) is predicted. Assuming that the ID-AD rela-
tionship is the same in humans as in mice, the human ad-
ministered dose isfirsttransformed into the internal dose
scale using the Michaelis-Menten function for mice, and
this internal dose is input into the ID-based multistage
model forall squamous cell carcinomas. Apoint estimate
of4.21 excess cancers/1000 exposed (with an upperbound
of 17.62/1000) is predicted usingthe internal dose. For all
squamous cell carcinomas in the F344/N male rat, point
estimates of 1.0 excess cancers/1000 (upper bound:
1.3/1000) and 2.9 excess cancers/1000 exposed (upper
bound: 3.9/1000) are predicted using the administered
dose and the internal dose, respectively.
As in the total metabolite ID risk assessment, we fo-
cus ontheprojectionofriskfora 1-ppmexposure nowus-
ingindividual metabolite (muconic acid and hydroquinone
glucuronide)basedinternal doses. Asabove, all squamous
cell carcinomas in B6C3F1 male mice is the tumorigenic
endpoint ofinterest. For simplicity, we described the tu-
mor response-dose relationship using the best-fitting
regression linethroughthe origin. Thiswasjustifiable be-
cause the tumorresponse-dose relationship was approx-
imately linear for all three dose scalings. Recall that an
oral dose of0.456mg/kg/daywas associated with a 1-ppm
inhalation dose. For this dose, a risk of 3.3/1000 is pro-
jected. This isvery similartoriskestimates fromthe mul-
tistage model. Performing calculations similar to those
described for the total metabolite ID, a risk of4.4/1000
and 4.1/1000 is projected for ID(HQG) and ID(MUC),
respectively. Similar calculations for all squamous cell




The basic conclusion from usinginternal dose informa-
tion in amultistage model-based risk assessment is that
the risk estimates based upon the total metabolite inter-
nal dose leads to a safe dose that is less than one order
ofmagnitude smallerthan a safe dose from arisk assess-
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ment based upon the administered doses. There are pos-
sible problems with this analysis that mustbeconsidered.
First, the ID-AD relationship was derived from an ex-
periment conducted with only one gavage dosing,
whereas the NTP tumorigenic response was based upon
two years of dosing. Therefore, this analysis is con-
founded by issues ofpossible repeated exposure and ag-
ing effects. Second, there is variability in the estimates
ofa andPin the Michaelis-Menten function that was not
explicitly considered in the risk estimation. Finally, the
multistage model for tumorigenesis and the Michaelis-
Menten ID-AD function may not be appropriate models.
The dose-rate studies may provide insight into the im-
portance of the type of exposure on possible benzene
health risks. If human metabolism is similar to the rat,
then administered dose risk estimation for chronic low-
dose exposures may actually overestimate the true risk.
In this scenario, concern should be focused on spike ex-
posures. If mouse metabolism is a better model for hu-
man metabolism, then the chronic exposures should be
ofgreater concern than the spike exposures. In human
exposure-based risk assessments where a cumulative ex-
posure measure was used, risks of3 to 11 excess cancer
deaths/1000 exposed have been suggested for a 1-ppm
lifetime (30 year) exposure (10). This range is roughly
what we observed forthe internal doseriskestimates and
may suggest that the mouse internal dose may be a use-
ful model for the human internal dose.
We discussed the use of individual metabolites in the
derivation of internal doses. The shape of the internal
dose-administered dose curve mustbereasonably well es-
tablished before an individual metabolite-based internal
dose is used. If data were available at some of the mid-
dle dose points (such as 15, 25, and 50 mg/kg for the
gavage dosings), a much better characterization ofthe in-
ternal dose-administered dose relationship may be pos-
sible.
We would like to consider some ways in which the risk
assessment process for benzene may be improved. Ongo-
ingresearch in the construction ofinternal dose for arisk
assessment ofbenzene include applying physiologically-
based pharmacokinetic models for modeling the disposi-
tion ofbenzene and measuring hemoglobin adducts as a
toxic metabolite surrogate.
The physiologically-based pharmacokinetic models pro-
vide a natural means ofmodeling repeated exposure so
that the internal dose may reflect the exposures used in
the chronic bioassays such as the NTP study. Addition-
ally, these models canbe used to compare different dose-
rate exposures. It is not clearhow sensitive these models
are relative to the choice of physiological parameters;
therefore, it is not clear that these models will provide
improvement to the risk assessment process.
Hemoglobin adducts are indicators ofthe sum ofmeta-
bolic activation/deactivation that has occurred. As such,
these adducts should take into account individual differ-
ences in metabolism. These adducts may correlate with
DNA adduct formation. Once such measures are devel-
oped, a natural equivalent dose for species extrapolation
may be available.
From the relatively small amount ofmetabolite and ki-
netic data available, we see that risk estimates for ben-
zene may well change as better internal dosimetry is
available. The total metabolite or individual metabolite
internal doses are an improvement over the administered
dose scales in that these doses reflect some ofthe meta-
bolic processingofan administered chemical. Clearly, this
is not the total picture. Ideally, we would like to consider
the relationship between the administered dose and the
effectin the target cellrelatedtothemechanism ofaction.
Agoodcandidate forthetargetcellsforbenzene leukemo-
genesis are the stem cells inthebone marrow. Additional
data ofthis type will allow a more satisfactory risk anal-
ysis ofbenzene to be performed.
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